RESEARCH STUDY

CancerLife: Patient-Driven Solution in Cancer Care

Official Title: Patient-Driven Solution in Cancer Care: Improving Outcomes Using a Digital Information and Communication Platform

The primary purpose of this study is to evaluate the use of a digital information and communication platform (DICP) in improving outcomes in patients with cancer and their caregivers.

Patients initiating and/or receiving systemic treatment for cancer will be enrolled in a nonblinded, randomized, controlled trial of a DICP in self-reporting and monitoring of cancer and cancer-treatment related symptoms compared with usual care. The study will require one (1) study encounter for consenting purposes.

Participants will be randomized 1:1 to two arms:

Arm A will be asked to download a mobile application called CancerLife. CancerLife is a patient facing messaging app that gives cancer survivors and caregivers the ability to update family and friends of their health status through their existing social networks and at the same collect psychosocial and symptom reports that can be shared with the patients care team. Participants will be provided with online or printed instructions on the use of CancerLife and receive a user guide that they can refer on demand. CancerLife is a stand-alone application that is NOT integrated into the patient’s electronic health record and will NOT trigger symptom alerts to the treatment team. Participants will be instructed to use the after-visit instructions provided to them by their treatment team for any symptoms or conditions that will require an evaluation by a healthcare provider.

Arm B will receive usual care provided for in the clinics. Usual care may vary between institutions, practices, and providers. Usual care may consist of but is not limited to any combination of the following: history and physical examination, review of systems, distress screening, symptom assessment measures, and/or interval quality of life measures.

Key Inclusion Criteria:
Age > 18 years, diagnosis of cancer, receiving systemic treatment (chemotherapy, biotherapy/immunotherapy, hormonal therapy) that is expected to continue for at least 3 treatment sessions (approximately 9 weeks) from the time of enrollment

Owns and able to use an electronic communication device (smart phone, tablet, laptop, desktop) and answer simple self-report questionnaires on their own

For more information, contact the Neuro-Oncology Clinical Trial Team at: Neuro.Oncology@jwci.org 310-829-8265

Clinical Trial Investigators
Garni Barkhoudarian, MD
Jose Carrillo, MD
Daniel Kelly, MD
Santosh Kesari, MD, PhD
Steven O’Day, MD
Marlon Garzo Saria, PhD, RN
Naveed Wagle, MD

Clinical Trial Team
Jaya Mini Gill, RN, BSN
Jaya.Gill@providence.org 310-582-7437
Annie Heng, RN, BSN
Annie.Heng@providence.org 310-582-7457
Hanh Nguyen, CRA
NguyenThuyH@jwci.org 310-582-7434
Ashley Archer, CRA
ArcherA@jwci.org 310-582-7460

Sponsor
CancerLife